Actively Recruiting
IL-33, sST2, and CRP in Panic Disorder
Led by Elazığ Mental Health and Diseases Hospital · Updated on 2026-03-04
80
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.
CONDITIONS
Official Title
IL-33, sST2, and CRP in Panic Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be between 18 and 65 years old
- Have a diagnosis of panic disorder according to DSM-5-TR and have panic attack symptoms
- Not have used any psychiatric medication before (drug-naive)
- Not have any other active psychiatric disorders besides panic disorder
- Not have hypertension, diabetes, kidney or liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
- Not have taken any medication or supplements in the past month
- Fully complete sociodemographic and scale questionnaires
- Volunteer to participate in the study
You will not qualify if you...
- Be younger than 18 or older than 65 years
- Not meet the diagnostic criteria for panic disorder or be in good health
- Have a history of psychiatric medication use
- Have any other psychiatric disorder besides panic disorder
- Have hypertension, diabetes, kidney or liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
- Have a body mass index (BMI) less than 18.5 or greater than 29.9 kg/m²
- Have taken any medication or supplements in the past month
- Incomplete sociodemographic or scale data
- Not volunteer to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Elazığ Mental Health and Diseases Hospital Psychiatry Clinic
Elâzığ, Elâzığ, Turkey (Türkiye), 23200
Actively Recruiting
Research Team
M
Mehmet Hamdi ÖRÜM, MD, Ass. Prof., Psychiatrist
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here